Mach7 Hit by VHA Program Halt but Reaffirms Commercial Growth Focus

Mach7 Technologies ( (AU:M7T) ) has provided an announcement.

Mach7 Technologies has confirmed that the U.S. Veterans Health Administration will halt its NextGen PACS program for the National Teleradiology Program, resulting in the termination of the multi‑vendor project in which Mach7 was a subcontractor. The decision means the VHA will retain its incumbent imaging vendor and that neither the already‑implemented Phase 1, covering limited go‑live in mammography and telestroke, nor the planned Phase 2 will proceed, despite Mach7 having met its initial contractual obligations. While management described the outcome as disappointing, they emphasised that the highly complex, bespoke government project demanded substantial resources and that its cancellation does not alter Mach7’s strategic focus on its broader commercial pipeline, where deal velocity and payment terms are more attractive, and on sustaining growth in recurring revenue and profitability.

The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.

More about Mach7 Technologies

Mach7 Technologies (ASX:M7T) is a medical imaging software provider that delivers advanced data management and diagnostic viewing solutions to healthcare organisations globally. Its flagship Enterprise Imaging Solution combines a vendor neutral archive, the eUnity enterprise diagnostic viewer and workflow tools, serving a broad customer base from large integrated delivery networks and national health systems to independent provider groups and private radiology practices.

Average Trading Volume: 309,431

Technical Sentiment Signal: Buy

Current Market Cap: A$130.4M

For an in-depth examination of M7T stock, go to TipRanks’ Overview page.